Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom : 2012/13 end of season results
Andrews, N and McMenamin, J and Durnall, H and Ellis, J and Lackenby, A and Robertson, C and von Wissmann, B and Cottrell, S and Smyth, B and Moore, C and Gunson, R and Zambon, M and Fleming, D and Pebody, R (2014) Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom : 2012/13 end of season results. Eurosurveillance, 19 (27). pp. 5-13. ISSN 1560-7917 (http://www.eurosurveillance.org/ViewArticle.aspx?A...)
Full text not available in this repository.Request a copyAbstract
The effectiveness of the 2012/13 trivalent seasonal influenza vaccine (TIV) was assessed using a test-negative case-control study of patients consulting primary care with influenza-like illness in the United Kingdom. Strain characterisation was undertaken on selected isolates. Vaccine effectiveness (VE) against confirmed influenza A(H3N2), A(H1N1) and B virus infection, adjusted for age, sex, surveillance scheme (i.e. setting) and month of sample collection was 26% (95% confidence interval (CI): -4 to 48), 73% (95% CI: 37 to 89) and 51% (95% CI: 34 to 63) respectively. There was an indication, although not significant, that VE declined by time since vaccination for influenza A(H3N2) (VE 50% within three months, 2% after three months, p=0.25). For influenza A(H3N2) this is the second season of low VE, contributing to the World Health Organization (WHO) recommendation that the 2013/14 influenza vaccine strain composition be changed to an A(H3N2) virus antigenically like cell-propagated prototype 2012/13 vaccine strain (A/Victoria/361/2011). The lower VE seen for type B is consistent with antigenic drift away from the 2012/13 vaccine strain. The majority of influenza B viruses analysed belong to the genetic clade 2 and were antigenically distinguishable from the 2012/13 vaccine virus B/Wisconsin/1/2010 clade 3. These findings supported the change to the WHO recommended influenza B vaccine component for 2013/14.
-
-
Item type: Article ID code: 51730 Dates: DateEvent10 July 2014PublishedKeywords: adolescent, adult, aged, case-control studies, child, Great Britain, hemagglutination inhibition tests, influenza A virus, H1N1 Subtype, influenza A virus, H3N2 Subtype, influenza B virus, influenza vaccines, influenza, human, primary health care, Sentinel Surveillance, sequence analysis, DNA, treatment outcome, vaccination, Public health. Hygiene. Preventive Medicine, Therapeutics. Pharmacology, Virology, Epidemiology, Public Health, Environmental and Occupational Health, SDG 3 - Good Health and Well-being Subjects: Medicine > Public aspects of medicine > Public health. Hygiene. Preventive Medicine
Medicine > Therapeutics. PharmacologyDepartment: Faculty of Science > Mathematics and Statistics Depositing user: Pure Administrator Date deposited: 18 Feb 2015 05:02 Last modified: 07 Jan 2024 23:46 Related URLs: URI: https://strathprints.strath.ac.uk/id/eprint/51730